CLINICAL NEWS
Carfilzomib Combination for Salvage Therapy
in Multiple Myeloma: Results from a
Real-World Setting
Despite the recent approval of several new drugs in multiple myeloma
(MM), including proteasome inhibitors and immunomodulatory agents,
the treatment of patients with relapsed and/or refractory disease is still
challenging. The proteasome inhibitor carfilzomib was approved by the
U.S. FDA in July 2012 based on data from a phase II trial showing an overall response rate (ORR) of 23.4 percent and a median response duration
of 7.8 months. These outcomes though, may differ in a non–clinical trial,
real-world setting.
In a retrospective, multicenter study recently published in Blood, Eli
Muchtar, MD, from the Institute of Hematology at the Rabin Medical
Center in Petah Tikva, Israel, and colleagues examined the safety and
efficacy of carfilzomib in patients with relapsed/refractory MM in 10
medical centers across Israel.
“Carfilzomib, especiall